(SAGE) Sage Therapeutic - Ratings and Ratios

Sage Therapeutics, Inc. (NASDAQ:SAGE) is a biopharmaceutical company specializing in the development and commercialization of innovative brain health medicines. The companys lead product, ZURZUVAE, is a neuroactive steroid that acts as a positive allosteric modulator of GABA receptors, targeting both synaptic and extrasynaptic receptors to treat postpartum depression in adults. Its pipeline includes SAGE-324, a novel GABA receptor PAM designed for chronic oral administration, primarily for seizures in developmental and epileptic encephalopathies. SAGE-319, another key candidate, is an extrasynaptic-preferring GABA receptor PAM aimed at addressing behavioral symptoms in neurodevelopmental disorders. The company is also advancing SAGE-817 and SAGE-039, focusing on acute and chronic brain health conditions through allosteric modulation of GABA and NMDA receptor systems, as well as an NMDA receptor negative allosteric modulator for neurodevelopmental disorders. Originally named Sterogen Biopharma, Inc., the company rebranded as Sage Therapeutics, Inc. in September 2011 and is now headquartered in Cambridge, Massachusetts.

As of the latest data, Sage Therapeutics, Inc. is valued at a market capitalization of $439.59 million. The stock currently trades at $7.19, with a price-to-sales ratio of 10.66, reflecting its revenue growth potential. The companys return on equity stands at -86.15%, indicating ongoing losses as it invests in R&D. Its price-to-book ratio of 0.93 suggests the market values its assets near their accounting value. The stocks average 20-day volume is 1,597,127 shares, with a 20-day simple moving average (SMA) of $7.23, 50-day SMA of $6.63, and 200-day SMA of $8.14. The average true range (ATR) of 0.34 highlights moderate volatility.